Population with or without treatment | Patients with rheumatoid arthritis OR juvenile idiopathic arthritis OR systemic lupus erythematosus OR systemic sclerosis OR psoriatic arthritis OR spondyloarthritis OR Sjögren’s syndrome OR vasculitis OR inflammatory myopathy OR dermatomyositis OR psoriasis OR Crohn’s disease OR ulcerative colitis |
---|---|
Intervention | yellow fever vaccine |
Comparison | Placebo OR no intervention |
Outcomes | immunization, safety, severe adverse events, viscerotropic disease associated with yellow fever vaccine, immunogenicity, response, effectiveness, efficacy, seroconversion, disease activity: DAS28, ACR 30/50/70. BASDAI, SLEDAI, HAQ / CHAQ, VASDAI, CMAS, MMT |